• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估反应率和睡眠障碍患病率:来自普萘洛尔治疗婴儿血管瘤研究的见解。

Assessing Response Rates and Sleep Disorder Prevalence: Insights from a Propranolol Treatment Study for Infantile Haemangiomas.

作者信息

Opri Francesca, Opri Roberta, Zaffanello Marco, Rigotti Erika

机构信息

Pediatric Clinic, Magalini Hospital, I-37069 Villafranca di Verona, Italy.

Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, Pediatric Clinic, University of Verona, I-37129 Verona, Italy.

出版信息

Children (Basel). 2024 Sep 4;11(9):1086. doi: 10.3390/children11091086.

DOI:10.3390/children11091086
PMID:39334619
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11430174/
Abstract

BACKGROUND

Infantile haemangiomas (IHs) sometimes require treatment with propranolol. Sleep disturbances are the most frequently reported side effects. Monitoring adverse drug events necessitates repeated hospital visits, which can be challenging during a pandemic.

OBJECTIVES

To explore the effectiveness of a new electronic questionnaire in identifying sleep disturbances related to treatment with propranolol and potential confounding factors. To evaluate the response rate to the questionnaire. To report the proportion of patients on propranolol with sleep disturbances.

METHODS

In an observational, prospective cohort study, caregivers provided clinical information during ambulatory visits and via an electronic questionnaire after an 8-week treatment course with propranolol and at the time of treatment interruption. Adverse drug reaction reporting forms were assessed for causality.

RESULTS

The questionnaire response rate was 91%, and the completion rate was 100%. A total of 59% of patients experienced sleep disturbances during propranolol treatment, which were considered adverse reactions. Sleep disorders were frequent during sleep regression phases and in subjects who fell asleep during physical contact with caregivers or bed-sharing with parents.

CONCLUSION

The application of this questionnaire allows for identifying adverse sleep events associated with propranolol in IHs and potential confounders. Counselling on sleep hygiene is recommended before treatment onset.

摘要

背景

婴儿血管瘤(IHs)有时需要使用普萘洛尔进行治疗。睡眠障碍是最常报告的副作用。监测药物不良事件需要多次住院就诊,在大流行期间这可能具有挑战性。

目的

探讨一种新的电子问卷在识别与普萘洛尔治疗相关的睡眠障碍及潜在混杂因素方面的有效性。评估问卷的回复率。报告使用普萘洛尔且有睡眠障碍的患者比例。

方法

在一项观察性前瞻性队列研究中,照料者在门诊就诊期间以及在普萘洛尔治疗8周疗程后和治疗中断时通过电子问卷提供临床信息。对药物不良反应报告表进行因果关系评估。

结果

问卷回复率为91%,完成率为100%。共有59%的患者在普萘洛尔治疗期间出现睡眠障碍,这些被视为不良反应。在睡眠倒退阶段以及在与照料者身体接触或与父母同床共枕时入睡的受试者中,睡眠障碍很常见。

结论

应用该问卷可以识别婴儿血管瘤患者中与普萘洛尔相关的不良睡眠事件及潜在混杂因素。建议在治疗开始前进行睡眠卫生咨询。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14e2/11430174/f0a6326777aa/children-11-01086-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14e2/11430174/f0a6326777aa/children-11-01086-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14e2/11430174/f0a6326777aa/children-11-01086-g001.jpg

相似文献

1
Assessing Response Rates and Sleep Disorder Prevalence: Insights from a Propranolol Treatment Study for Infantile Haemangiomas.评估反应率和睡眠障碍患病率:来自普萘洛尔治疗婴儿血管瘤研究的见解。
Children (Basel). 2024 Sep 4;11(9):1086. doi: 10.3390/children11091086.
2
Interventions for infantile haemangiomas of the skin.皮肤婴儿血管瘤的干预措施。
Cochrane Database Syst Rev. 2018 Apr 18;4(4):CD006545. doi: 10.1002/14651858.CD006545.pub3.
3
Propranolol (Hemangiol) and severe infantile haemangiomas. The drug of first choice.普萘洛尔(Hemangiol)与重度婴儿血管瘤。首选药物。
Prescrire Int. 2015 Jul;24(162):173-6.
4
Oral Nadolol for Children with Infantile Hemangiomas and Sleep Disturbances with Oral Propranolol.口服纳多洛尔治疗患有婴儿血管瘤且伴有口服普萘洛尔所致睡眠障碍的儿童。
Pediatr Dermatol. 2015 Nov-Dec;32(6):853-7. doi: 10.1111/pde.12686. Epub 2015 Oct 8.
5
The effectiveness of propranolol in treating infantile haemangiomas: a meta-analysis including 35 studies.普萘洛尔治疗婴幼儿血管瘤的有效性:一项纳入35项研究的荟萃分析。
Br J Clin Pharmacol. 2014 Jul;78(1):44-57. doi: 10.1111/bcp.12235.
6
Use of propranolol for treatment of infantile haemangiomas in an outpatient setting.在门诊环境中使用普萘洛尔治疗婴儿血管瘤。
J Paediatr Child Health. 2012 Oct;48(10):902-6. doi: 10.1111/j.1440-1754.2012.02521.x. Epub 2012 Aug 16.
7
Cardiac side effects of propranolol in infants treated for infantile haemangiomas.普萘洛尔治疗婴儿血管瘤时的心脏副作用。
Cardiol Young. 2023 Dec;33(12):2616-2620. doi: 10.1017/S1047951123000847. Epub 2023 Apr 20.
8
Propranolol for infantile haemangiomas: experience from a tertiary center.普萘洛尔治疗婴儿血管瘤:来自三级医疗中心的经验
J Cutan Aesthet Surg. 2014 Jan;7(1):37-41. doi: 10.4103/0974-2077.129975.
9
Propranolol in the treatment of infantile haemangiomas: lessons from the European Propranolol In the Treatment of Complicated Haemangiomas (PITCH) Taskforce survey.普萘洛尔治疗婴儿血管瘤:来自欧洲普萘洛尔治疗复杂血管瘤(PITCH)工作组调查的经验。
Br J Dermatol. 2016 Mar;174(3):594-601. doi: 10.1111/bjd.14233. Epub 2015 Dec 26.
10
Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas.普萘洛尔、马来酸噻吗洛尔及其二者联合治疗浅表性婴幼儿血管瘤的疗效与安全性评估。
Br J Oral Maxillofac Surg. 2015 Nov;53(9):836-40. doi: 10.1016/j.bjoms.2015.09.005. Epub 2015 Sep 28.

引用本文的文献

1
An endothelial SOX18-mevalonate pathway axis enables repurposing of statins for infantile hemangioma.内皮细胞SOX18-甲羟戊酸途径轴使得他汀类药物可用于婴儿血管瘤的治疗。
J Clin Invest. 2025 Feb 25;135(7):e179782. doi: 10.1172/JCI179782.
2
Efficacy and safety assessment of propranolol tablets vs. oral solution for infantile hemangioma: a retrospective study in China.普萘洛尔片与口服液治疗婴幼儿血管瘤的疗效及安全性评估:一项中国的回顾性研究
Front Pediatr. 2025 Feb 4;13:1542348. doi: 10.3389/fped.2025.1542348. eCollection 2025.

本文引用的文献

1
Infantile hemangioma: the common and enigmatic vascular tumor.婴儿血管瘤:常见且神秘的血管肿瘤。
J Clin Invest. 2024 Apr 15;134(8):e172836. doi: 10.1172/JCI172836.
2
Educator's blueprint: A how-to guide for survey design.教育者蓝图:调查设计操作指南
AEM Educ Train. 2022 Aug 23;6(4):e10796. doi: 10.1002/aet2.10796. eCollection 2022 Aug.
3
Update on Treatment of Infantile Hemangiomas: What's New in the Last Five Years?婴儿血管瘤治疗的最新进展:过去五年有哪些新变化?
Front Pharmacol. 2022 May 26;13:879602. doi: 10.3389/fphar.2022.879602. eCollection 2022.
4
Propranolol in the Treatment of Infantile Hemangiomas.普萘洛尔治疗婴幼儿血管瘤
Clin Cosmet Investig Dermatol. 2021 Sep 3;14:1155-1163. doi: 10.2147/CCID.S332625. eCollection 2021.
5
Adverse Drug Reactions Following Propranolol in Infantile Hemangioma.普萘洛尔治疗婴儿血管瘤后的药物不良反应。
Indian Pediatr. 2021 Aug 15;58(8):753-755. Epub 2021 Mar 26.
6
Sleep behavior of infants with infantile hemangioma treated with propranolol-a cohort study.接受普萘洛尔治疗的婴幼儿血管瘤患儿的睡眠行为:一项队列研究。
Eur J Pediatr. 2021 Aug;180(8):2655-2668. doi: 10.1007/s00431-021-04147-3. Epub 2021 Jun 18.
7
Remote health diagnosis and monitoring in the time of COVID-19.远程健康诊断和监测在 COVID-19 期间。
Physiol Meas. 2020 Nov 10;41(10):10TR01. doi: 10.1088/1361-6579/abba0a.
8
Behavioral insomnia in infants and young children.婴幼儿行为性失眠
Clin Exp Pediatr. 2021 Mar;64(3):111-116. doi: 10.3345/cep.2020.00052. Epub 2020 Jul 15.
9
Clinical Practice Guideline for the Management of Infantile Hemangiomas.婴幼儿血管瘤管理临床实践指南。
Pediatrics. 2019 Jan;143(1). doi: 10.1542/peds.2018-3475.
10
The preventable proportion of healthcare-associated infections 2005-2016: Systematic review and meta-analysis.2005-2016 年可预防的医疗保健相关感染比例:系统评价和荟萃分析。
Infect Control Hosp Epidemiol. 2018 Nov;39(11):1277-1295. doi: 10.1017/ice.2018.183. Epub 2018 Sep 20.